Table 5. Response Summary of Osimertinib according to the Source of T790M Status.
| Total (n=88) | Tissue T790M+ (n=45) | Plasma T790M+ (n=54) | Tissue T790M+ & Plasma T790M+ (n=11) | Tissue T790M+ & Plasma T790M- (n=19) | Tissue T790M− & Plasma T790M+ (n=13) | |
|---|---|---|---|---|---|---|
| Best response | ||||||
| CR or PR | 39 (44.3) | 26 (57.8) | 19 (35.2) | 6 (54.5) | 10 (52.6) | 1 (7.6) |
| SD | 30 (34.1) | 15 (33.3) | 16 (29.6) | 1 (9.1) | 9 (47.4) | 3 (23.1) |
| PD | 13 (14.8) | 3 (6.7) | 13 (24.1) | 3 (27.3) | 0 (0.0) | 7 (53.8) |
| Not evaluable | 6 (6.8) | 1 (2.2) | 6 (11.1) | 1 (9.1) | 0 (0.0) | 2 (15.4) |
| ORR (95% CI), (%) | 44.3 (34.4–57.2) | 57.8 (43.3–71.0) | 35.2 (23.8–48.6) | 54.5 (28.0–78.8) | 52.6 (31.7–72.7) | 7.6 (0.0–35.4) |
| DCR (95% CI), (%) | 78.4 (68.6–85.8) | 91.1 (78.7–97.0) | 64.8 (51.5–76.2) | 63.6 (35.2–85.0) | 100.0 (80.2–100.0) | 30.8 (12.4–58.0) |
CR, complete response; PR, partial response; SD, stable disease; ORR, objective response rate; DCR, disease control rate; CI, confidence interval
Variables are presented as a number (percentage) unless otherwise noticed.